$COEP solid company here, hot bio sector, huge news for the company.

"We are delighted to expand our field of use to now include pandemic and emergency situations, as it now broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

Check out the news: bit.ly/48mr5oR